CRNX -
Crinetics Pharmaceuticals, Inc.
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 41.91 1.09 (2.6%) |
0.02 (0.05%) |
-0.12 (-0.28%) |
-0.35 (-0.82%) |
0.06 (0.14%) |
1.39 (3.34%) |
--- |
0.06 (0.14%) |
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Earnings & Ratios
- Basic EPS:
- -1.23
- Diluted EPS:
- -1.23
- Basic P/E:
- -34.9593
- Diluted P/E:
- -34.9593
- RSI(14) 1m:
- 37.45
- VWAP:
- 43.03
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Jan 04, 2026 21:00
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Dec 03, 2025 13:00
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday
Nov 07, 2025 21:16
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 10, 2025 20:41
Is Crinetics Pharmaceuticals Stock a Buy?
Sep 28, 2025 12:30
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday
Sep 26, 2025 14:23
12 Health Care Stocks Moving In Friday's Pre-Market Session
Sep 26, 2025 12:10
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Jul 13, 2025 21:45
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
May 23, 2025 12:00
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Feb 06, 2025 21:35